What type of study is this?

This is a In Vitro Study study (also classified as: Animal Study).

August 21, 2025Open Access

Figure 5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Dual treatment significantly decreases cell viability in 3D LNCaP95 spheroids and organoids.
The combination of A-1331852 and S63845 showed a strong synergy with P < 0.0001.
Assessments utilized a 3D CellTiter-Glo method to evaluate viability after 72 hours.
Highlights the potential for enhanced efficacy in prostate cancer treatments with these drug combinations.

Abstract

Dual targeting of Bcl-xL and Mcl-1 leads to synergistic decreases in cell viability in 3D LNCaP95 spheroids and the LuCaP 167CR organoid model. Dual treatment of navitoclax and A-1331852 with S63845 in 3D prostate cancer models. A, Representative images for each treatment condition before treatment and 24, 48, and 72 hours after treatment. B and C, Viability of spheroids measured by 3D CellTiter-Glo after 72 hours of treatment. Plots show mean ± SD. ****, P D–F) or navitoclax and S63845 (G–I). Drug curves (D and G) show mean ± SD. Dose–response matrices (E and H) and Bliss synergy plots (F and I) were generated using the Synergyfinder+ R package to evaluate synergy. All spheroid experiments were completed in triplicate. Organoid experiments had six technical replicates with three biological replicates.

Figure 5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Abstract

Cite This Study

Also Consider

Also Consider